{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:25:57Z","timestamp":1762097157313,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per La Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["5M-2019-23680413"],"award-info":[{"award-number":["5M-2019-23680413"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bcp.2025.117127","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:59:17Z","timestamp":1752566357000},"page":"117127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structure-guided combination of novel CFTR correctors to improve the function of F508del-CFTR in airway epithelial cells"],"prefix":"10.1016","volume":"240","author":[{"given":"Dario","family":"Lunaccio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Allegretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Scarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Salis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Tasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Brullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazzareno","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cichero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Millo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-4079","authenticated-orcid":false,"given":"Onofrio","family":"Laselva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117127_b0005","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2025.117127_b0010","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jcf.2022.09.010","article-title":"Structure basis of CFTR folding, function and pharmacology","volume":"22","author":"Hwang","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"16","key":"10.1016\/j.bcp.2025.117127_b0015","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s00018-008-8249-1","article-title":"Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces","volume":"65","author":"Mornon","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2025.117127_b0020","article-title":"The era of CFTR modulators: improvements made and remaining challenges","volume":"16","author":"Cuevas-Ocana","year":"2020","journal-title":"Breathe (Sheff.)"},{"key":"10.1016\/j.bcp.2025.117127_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116120","article-title":"Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms","volume":"265","author":"Cao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117127_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coph.2017.09.014","article-title":"Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis","volume":"34","author":"Mijnders","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117127_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12081321","article-title":"Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis","volume":"12","author":"Silva","year":"2022","journal-title":"J Pers Med"},{"issue":"7","key":"10.1016\/j.bcp.2025.117127_b0040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores DeltaF508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117127_b0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1124\/mol.114.092478","article-title":"Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy","volume":"86","author":"Phuan","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"42","key":"10.1016\/j.bcp.2025.117127_b0050","doi-asserted-by":"crossref","first-page":"25636","DOI":"10.1074\/jbc.M115.671925","article-title":"Combination of Correctors Rescue DeltaF508-CFTR by Reducing Its Association with Hsp40 and Hsp27","volume":"290","author":"Lopes-Pacheco","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2025.117127_b0055","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bcp.2025.117127_b0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2016.09.005","article-title":"The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain","volume":"119","author":"Laselva","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"46","key":"10.1016\/j.bcp.2025.117127_b0065","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.bcp.2025.117127_b0070","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/mol.118.111799","article-title":"Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains","volume":"93","author":"Laselva","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"18","key":"10.1016\/j.bcp.2025.117127_b0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"issue":"6617","key":"10.1016\/j.bcp.2025.117127_b0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of Delta508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.bcp.2025.117127_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612838","article-title":"Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2","volume":"24","author":"Bongiorno","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117127_b0090","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+ tezacaftor+ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator","author":"Laselva","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2025.117127_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","author":"Veit","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"10","key":"10.1016\/j.bcp.2025.117127_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105262","article-title":"Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117127_b0105","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.bcp.2025.117127_b0110","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1074\/jbc.M110.184267","article-title":"Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations","volume":"286","author":"Pedemonte","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117127_b0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2015.05.030","article-title":"Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis","volume":"99","author":"Pesce","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117127_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejmech.2017.12.030","article-title":"Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools","volume":"144","author":"Liessi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2025.117127_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/biom11101417","article-title":"NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis","volume":"11","author":"Brandas","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117127_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112833","article-title":"Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays","volume":"208","author":"Parodi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2025.117127_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ph16121702","article-title":"In Silico and In Vitro Evaluation of the Mechanism of Action of Three VX809-Based Hybrid Derivatives as Correctors of the F508del CFTR Protein","volume":"16","author":"Baroni","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10.1016\/j.bcp.2025.117127_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080804","article-title":"Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)","volume":"8","author":"Chin","year":"2019","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.bcp.2025.117127_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131764","article-title":"Olive Leaf Extract (OLE) as a Novel Antioxidant That Ameliorates the Inflammatory Response in Cystic Fibrosis","volume":"12","author":"Allegretta","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117127_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.905468","article-title":"Insulin-Like Growth Factor Binding Protein (IGFBP-6) as a Novel Regulator of Inflammatory Response in Cystic Fibrosis Airway Cells","volume":"9","author":"Laselva","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117127_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10040209","article-title":"Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators","volume":"10","author":"Laselva","year":"2020","journal-title":"J Pers Med"},{"issue":"4","key":"10.1016\/j.bcp.2025.117127_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11040301","article-title":"Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA(TM)","volume":"11","author":"Laselva","year":"2021","journal-title":"J Pers Med"},{"issue":"10","key":"10.1016\/j.bcp.2025.117127_b0165","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1096\/fba.2019-00039","article-title":"Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis-causing mutation","volume":"1","author":"Laselva","year":"2019","journal-title":"FASEB Bioadv."},{"issue":"3","key":"10.1016\/j.bcp.2025.117127_b0170","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00970-2024","article-title":"Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor\/tezacaftor\/ivacaftor is clinical strain-dependent in patient-derived nasal cells","volume":"11","author":"Allegretta","year":"2025","journal-title":"ERJ Open Res"},{"issue":"8","key":"10.1016\/j.bcp.2025.117127_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082132","article-title":"Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells","volume":"10","author":"Laselva","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117127_b0180","article-title":"Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation","author":"Oren","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"Pt 6(1","key":"10.1016\/j.bcp.2025.117127_b0185","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1107\/S0907444902003451","article-title":"The Protein Data Bank","volume":"58","author":"Berman","year":"2002","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"1","key":"10.1016\/j.bcp.2025.117127_b0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117127_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091316","article-title":"Novel Thiazole-Based SIRT2 Inhibitors Discovered via Molecular Modelling Studies and Enzymatic Assays","volume":"16","author":"Abbotto","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.bcp.2025.117127_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119363","article-title":"Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors","volume":"24","author":"Scarano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117127_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1370676","article-title":"Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters","volume":"15","author":"Taniguchi","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"23","key":"10.1016\/j.bcp.2025.117127_b0210","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1111\/jcmm.17605","article-title":"Screening by high-throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies","volume":"26","author":"de Melo","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117127_b0215","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/2472555220962001","article-title":"Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR","volume":"26","author":"Smith","year":"2021","journal-title":"SLAS Discov"},{"issue":"3","key":"10.1016\/j.bcp.2025.117127_b0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/2472630317692561","article-title":"High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations","volume":"22","author":"Liang","year":"2017","journal-title":"SLAS Technol."},{"key":"10.1016\/j.bcp.2025.117127_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116691","article-title":"Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis","volume":"276","author":"Barreca","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117127_b0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","article-title":"Molecular Structure of the Human CFTR Ion Channel","volume":"169","author":"Liu","year":"2017","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2025.117127_b0235","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.stemcr.2021.09.020","article-title":"A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients","volume":"16","author":"Jiang","year":"2021","journal-title":"Stem Cell Rep."},{"issue":"19","key":"10.1016\/j.bcp.2025.117127_b0240","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.bcp.2025.117127_b0245","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117127_b0250","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300391","article-title":"Cyclic diacyl thioureas enhance activity of corrector Lumacaftor on F508del-CFTR","volume":"19","author":"Spallarossa","year":"2024","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.bcp.2025.117127_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030274","article-title":"Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays","volume":"15","author":"Parodi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.bcp.2025.117127_b0260","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2174\/1573406416666200306114300","article-title":"Synthesis and Structure-activity Relationship of Aminoarylthiazole Derivatives as Potential Potentiators of the Chloride Transport Defect in Cystic Fibrosis","volume":"17","author":"Liessi","year":"2021","journal-title":"Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2025.117127_b0265","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1021\/acs.jmedchem.4c00685","article-title":"Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)","volume":"67","author":"Vaccarin","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2025.117127_b0270","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1021\/acs.jmedchem.3c01790","article-title":"Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector","volume":"67","author":"Pizzonero","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117127_b0275","article-title":"Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants","author":"Laselva","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.bcp.2025.117127_b0280","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jcf.2019.12.001","article-title":"Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action","volume":"19","author":"Laselva","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.bcp.2025.117127_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121296","article-title":"Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators","volume":"14","author":"Sabbadini","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2025.117127_b0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2025.117127_b0295","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117127_b0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jmb.2014.07.026","article-title":"Restoration of NBD1 thermal stability is necessary and sufficient to correct \u0394F508 CFTR folding and assembly","volume":"427","author":"He","year":"2015","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117127_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081174","article-title":"Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis","volume":"12","author":"Gunawardena","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117127_b0310","article-title":"Deleterious effect of P. aeruginosa on F508del-CFTR rescued by Elexacaftor\/Tezacaftor\/Ivacaftor is clinical-strain dependent in patient-derived nasal cells","author":"Allegretta","year":"2024","journal-title":"ERJ Open Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117127_b0315","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/mol.115.099689","article-title":"Potentiators of Defective DeltaF508-CFTR Gating that Do Not Interfere with Corrector Action","volume":"88","author":"Phuan","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"14","key":"10.1016\/j.bcp.2025.117127_b0320","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1016\/j.cell.2024.04.046","article-title":"Structure-based discovery of CFTR potentiators and inhibitors","volume":"187","author":"Liu","year":"2024","journal-title":"Cell"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:23:49Z","timestamp":1762097029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225003922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"alternative-id":["S0006295225003922"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117127","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided combination of novel CFTR correctors to improve the function of F508del-CFTR in airway epithelial cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117127"}}